This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLESTEROL CLOFIBRATE

(Stroke. 1973;4:684.)
© 1973 American Heart Association, Inc.

---

The Treatment of Cerebrovascular Disease With Clofibrate

Final Report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section

THE VETERANS ADMINISTRATION COOPERATIVE STUDY GROUP

A cooperative study in 20 Veterans Administration hospitals investigated the effect of clofibrate on morbidity and mortality due to atherosclerotic vascular disease in men with either an established cerebral infarction or transient cerebrovascular ischemic attacks (TIA). Follow-up observations were made for up to 4.5 years in 532 patients assigned on a random basis to placebo medication or to treatment with 2 gm of clofibrate daily. Baseline and follow-up cholesterol and triglyceride levels were measured.

Recurrence of cerebral infarction was increased in patients receiving clofibrate as compared to controls. The incidence of new myocardial infarction and new TIA was similar in both groups. Despite the more frequent strokes in treated patients, they had a decrease in mortality, partially explained by a lower death rate from these recurrences. There was no correlation between pretreatment lipid (cholesterol and triglyceride) values and the result of therapy. Use of clofibrate, however, was associated with a slight reduction of cholesterol and a sustained fall in triglyceride.

These findings do not support recently published reports that clofibrate reduces the occurrence of myocardial ischemia; however, the investigative design and type of data collected in these various studies are different and make it difficult to compare results.

Key Words: atherosclerosis • myocardial infarction • lipids • lipid reduction • collaborative investigation • stroke • stroke morbidity • stroke mortality

This article has been cited by other articles:

				S. R. Freeman, A. L. Drake, L. F. Heilig, M. Graber, K. McNealy, L. M. Schilling, and R. P. Dellavalle Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis. J Natl Cancer Inst, November 1, 2006; 98(21): 1538 - 1546. [Abstract] [Full Text] [PDF]

				H. C. Bucher, L. E. Griffith, and G. H. Guyatt Systematic Review on the Risk and Benefit of Different Cholesterol-Lowering Interventions Arterioscler. Thromb. Vasc. Biol., February 1, 1999; 19(2): 187 - 195. [Abstract] [Full Text] [PDF]

				J. F. Plehn, B. R. Davis, F. M. Sacks, J. L. Rouleau, M. A. Pfeffer, V. Bernstein, T. E. Cuddy, L. A. Moye, L. B. Piller, J. Rutherford, et al. Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin : The Cholesterol and Recurrent Events (CARE) Study Circulation, January 19, 1999; 99(2): 216 - 223. [Abstract] [Full Text] [PDF]

				G. Davey Smith, S. Ebrahim, J. R. Crouse III, R. P. Byington, H. M. Hoen, and C. D. Furberg Lowering of Cholesterol Levels and the Risk of Stroke Arch Intern Med, January 12, 1998; 158(1): 98 - 99. [Full Text] [PDF]

				L Bonneux, J J Barendregt, U Ravnskov, L E Ramsay, W W Yeo, P R Jackson, T A Sheldon, F Song, J Millo, C L M Sudlow, et al. Ischaemic heart disease and cholesterol There's more to heart disease than cholesterol BMJ, April 16, 1994; 308(6935): 1038 - 1041. [Full Text]